Research programme: metabolic disorders therapy - Metabolex/Ortho-McNeil

Drug Profile

Research programme: metabolic disorders therapy - Metabolex/Ortho-McNeil

Alternative Names: MBX 213

Latest Information Update: 20 Dec 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ortho-McNeil
  • Developer CymaBay Therapeutics
  • Class Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 10 Dec 2013 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 27 Sep 2004 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top